(Q27690917)

Hart BW

series ordinal

2

1 reference

Grewal IS

series ordinal

3

1 reference

publication date

2009

1 reference

published in

Monoclonal Antibodies

4 references

27 September 2019

27 November 2019

13 December 2019

1

1 reference

issue

1

1 reference

page(s)

2-11

1 reference

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715182

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715182

The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715182

Duration of chronic toxicity studies for biotechnology-derived pharmaceuticals: is 6 months still appropriate?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715182

Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715182

Natalizumab and progressive multifocal leucoencephalopathy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715182

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715182

Potent antibody therapeutics by design

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715182

Antibody targeted drugs as cancer therapeutics

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715182

Antibody engineering for the development of therapeutic antibodies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715182

Human antibodies from transgenic animals

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715182

Selecting and screening recombinant antibody libraries

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715182

Tolerability and safety of rituximab (MabThera).

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715182

Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715182

Preclinical safety testing of biotechnology-derived pharmaceuticals: understanding the issues and addressing the challenges

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715182

Therapeutic antibodies for human diseases at the dawn of the twenty-first century

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715182

Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715182

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715182

Clinical trials of antibody therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715182

Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715182

Engineering therapeutic monoclonal antibodies

29 September 2017

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.1.7377

Flexibility--the guiding principle for antibody manufacturing

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.1.7377

Preclinical safety testing of monoclonal antibodies: the significance of species relevance.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.1.7377

Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.1.7377

Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FMABS.1.1.7377

International Conference on Harmonisation; guidance on S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals; availability. Notice.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715182

Clinical and immunologic effects of a PRIMATIZED anti-CD4 monoclonal antibody in active rheumatoid arthritis: results of a phase I, single dose, dose escalating trial.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2715182

Inhibition of contact sensitivity in human CD4+ transgenic mice by human CD4-specific monoclonal antibodies: CD4+ T-cell depletion is not required

27 November 2018

1 reference

12 December 2020

Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4

1 reference

12 December 2020

International Conference on Harmonisation; guidance on the duration of chronic toxicity testing in animals (rodent and nonrodent toxicity testing); availability. Notice. Food and Drug Administration, HHS

1 reference

12 December 2020

An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen

1 reference

12 December 2020

The problem with potency

1 reference

12 December 2020

Monoclonal antibody successes in the clinic

1 reference

12 December 2020

Monoclonal antibody therapy of cancer

1 reference

12 December 2020

Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies

1 reference

12 December 2020

International Conference on Harmonisation; Guidance on S8 Immunotoxicity Studies for Human Pharmaceuticals; availability. Notice

1 reference

12 December 2020

Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products (EMEA/CHMP/SWP/28367/07 Rev. 1.

1 reference

12 December 2020

Immunotoxicity assessment of biotechnology products: a regulatory point of view

1 reference

12 December 2020

Points to consider in the manufacture and testing of monoclonal antibody products for human use (1997). U.S. Food and Drug Administration Center for Biologics Evaluation and Research

1 reference

12 December 2020

Identifiers

DOI

10.4161/MABS.1.1.7377

0 references

1 reference

PubMed publication ID

20046568

1 reference